- Motley Fool•5 hours ago
This dynamic duo appears to be on track to give Gilead's portfolio of hepatitis C products a run for its money.
- Investor's Business Daily•yesterday
Regeneron fell after a combo therapy with Eylea for treating wet age-related macular degeneration performed worse than Eylea alone. Ophthotech also tumbled.
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
|Bid||79.15 x 200|
|Ask||79.39 x 100|
|Day's Range||78.05 - 79.63|
|52wk Range||76.67 - 111.11|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||6.94|
|Avg Vol (3m)||10,503,607|
|Dividend & Yield||1.88 (2.41%)|